<DOC>
	<DOCNO>NCT00003423</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know combination chemotherapy regimen effective non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness different regimen combination chemotherapy treat child newly diagnose non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether event-free survival child T-cell non-Hodgkin 's lymphoma ( NHL ) improve addition third intensification block 35 week . II . Determine biology treatment response T-cell NHL T-cell acute lymphocytic leukemia treat identical leukemia type protocol receive third intensification block . III . Improve outcome 25 % child remission eight week addition block sustain intensification high dose methotrexate continue treatment . OUTLINE : Patients receive induction therapy day 1-28 . Patients receive supportive oral prednisolone daily three dos week 1-4 , vincristine IV weekly 5 week start day 1 , asparaginase intramuscularly subcutaneously three time week begin day 4 , methotrexate intrathecally day 1 8 . Patients meet certain criterion give first intensification therapy begin day 29 . Patients receive three dos oral prednisolone , vincristine IV day 1 , daunorubicin IV 6 hour day 1 2 , etoposide IV 4 hour day 1-5 , cytarabine IV every 12 hour bolus injection day 1-5 , oral thioguanine daily day 1-5 , methotrexate intrathecally induction therapy . Patients follow 8 week . Those patient experience remission receive third intensification block 35 week . All patient receive three methotrexate infusion follow continuation therapy begin week 14 . As continuation therapy , patient receive oral mercaptopurine daily , oral methotrexate weekly , vincristine IV every 4 week , oral prednisolone 5 day every 4 week , intrathecal methotrexate every 12 week begin week 23 100 week start treatment . Continuation therapy interrupt week 20 second intensification therapy . For second intensification therapy , patient receive oral prednisolone daily 5 day , single dose vincristine day 1 , daunorubicin IV 6 hour day 1 2 , etoposide IV 4 hour day 1-5 , bolus injection cytarabine every 12 hour day 1-5 , oral thioguanine daily day 1-5 , intrathecal methotrexate induction therapy . Continuation therapy re-starts week 23 . Patients receive third intensification therapy begin week 35 . For third intensification therapy , patient receive three dos oral dexamethasone , IV vincristine day 1 week 35-38 , subcutaneous asparaginase 9 day week 35-38 , intrathecal methotrexate day 1 week 35 39 , IV cyclophosphamide day 1 week 39 41 , subcutaneous IV cytarabine daily day 1-4 week 39- 42 , oral thioguanine daily week 39-42 . Continuation therapy re-starts week 42/43 . Some patient may receive radiotherapy chemotherapy . Patients follow every month 1 year , every 2 month next year , every 6 month next 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 100 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose stage I , II , III , IV Tcell nonHodgkin 's lymphoma No Tcell large anaplastic , peripheral Tcell lymphoma , Tcell lymphoblastic leukemia No great 25 % blast bone marrow PATIENT CHARACTERISTICS : Age : Under 15 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>April 2001</verification_date>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
</DOC>